ClinicalTrials.gg
CompletedNCT05669781Updated Jan 3, 2023

The Effects of Combined Gum-chewing and Parenteral Metoclopramide on Post-operative Ileus

A Phase 4 interventional study of Metoclopramide 10mg and Gum and metoclopramide in Ileus Postoperative, sponsored by Ikechukwu Bartholomew Ulasi. Completed at 1 site in Nigeria. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-03.

Sponsored by Ikechukwu Bartholomew Ulasi · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Oct 2018, registered Dec 2022).
Phase
Phase 4
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Study summary

A delay in the return of bowel function is a common occurrence after abdominal surgeries.1 The goal of this study was to test the effect of the combined use of chewing a gum and administering metoclopramide intravenously on the duration of this natural delay in the return of bowel function after abdominal surgeries. Patients were grouped into four: the first group received both gum and metoclopramide; the second group received only gum; the third group received only metoclopramide, while the fourth group (the control group) received sterile water for injection. The groups were compared for the time taken for bowel function to return and the duration of hospital stay.

Read the detailed description

This was a prospective randomized controlled trial that recruited all patients requiring elective abdominal surgery, aged 16-65years. Abdominal emergency surgeries and structural or functional inability to chew gum constituted the exclusion criteria. A written informed consent was obtained from all eligible patients.

Considering an effect size of 0.8(Cohen, 1962)2 at a power of 80% with 95% level of confidence and type-1 error of 5%, a total sample size of 105 study participants was obtained, having considered an attrition rate of 5%. Study participants were randomized into 4 groups (a gum-metoclopramide {GM} group, a gum-only {G} group, a metoclopramide-only {M} group and a control {C} group) using blocked sequence randomization.

Data was obtained through a detailed history and physical examination and include demographic variables like age and gender. Medical history of previous abdominal surgeries and any comorbidity like chronic constipation, diabetes mellitus, parkinsonism, renal or cardiac disease were sought and allergy to metoclopramide or gum noted. Body Mass Index (BMI) and relevant investigation results were recorded. Other pre- and intra-operative data recorded included: clinical diagnosis, American Society of Anaesthesiologists (ASA) grade, type of anaesthesia, cadre of surgeon, surgical access (laparoscopic versus open), length of skin incision, intra-operative blood loss, total intra-operative fluid administered, duration of surgery, surgical procedure done and duration of anaesthesia. Recorded post-operatively were time to passage of first flatus, time to passage of first feces, time to initial recording of bowel sounds, time to tolerance of normal diet, day of first ambulation, length of hospital stay, cost of hospital stay and post-operative complications.

Informed consent was obtained from all patients that met the inclusion criteria. All patients for elective surgery were admitted at least a day prior to surgery and kept on nothing by mouth from 12midnight on the eve of surgery. Patients were given intravenous metronidazole and ceftriaxone at the induction of anaesthesia. All the patients had general anaesthesia. Abdominal skin incision was made by the surgeon who was either a senior registrar or consultant in general surgery and to whom the patient's group was undisclosed. Standard procedures (surgical and anesthetic) relevant for each case were carried out. The group assigned to each patient was known only to the research assistants (a house surgeon and the nursing staff) who alone administered the intervention to the appropriate groups. Although what was used for intravenous intervention was undisclosed to the patients in the GM, M and C groups, it was not possible to blind patients who received gum only (G group).

All interventions were commenced from the 1st post-operative day. Patients in the gum-only(G) group were given one stick of sugar free gum (Orbit, Wrigley, US) 3 times 8 hourly daily (in the morning, afternoon and in the evening) till either first flatus or feces was passed with an instruction to chew for 15 minutes(only) without swallowing the chewed gum. The criteria for discontinuing each intervention was not disclosed to the patients. The gum was given to patients at a fixed interval to help monitor compliance. Patients in the metoclopramide-only (M) group received intravenous metoclopramide (Philometro, Hubei Tianyao) 10mg 8hourly for the first 72hours post-operatively. The gum-metoclopramide (GM) group received intravenous metoclopramide and also chewed gum using the protocol earlier described for gum only and metoclopramide only groups. Patients assigned to the control (C) group received 10ml of sterile water intravenously 8hourly for the first 72hours post-operatively.

All patients were asked to notify the nursing staff at first passage of flatus. A blinded doctor visited the patients 8hourly and recorded the time of the first bowel sounds, passage of flatus, and defecation. After giving each intervention, the type and time of intervention was documented in an identifier-free patient's questionnaire. The first time of flatus and defecation was recorded based on the patient's own statements. Prolonged post-operative ileus was defined as ileus lasting more than 5days following laparotomy or greater than 3days following laparoscopic surgery.3 Nasogastric tube was removed on the day of return of bowel function. The total duration of hospital stay, calculated from the first post-operative day to the day of discharge, was recorded.

The association between categorical and numerical peri-operative factors with prolonged post-operative ileus was analyzed using the Chi-square (and Fisher's exact) test and independent t-test (and Mann Whitney-U test) respectively. Comparison of groups in terms of the duration of post-operative ileus and duration of hospital stay was done using analysis of variance (ANOVA). Secondary endpoints compared between the groups included time to first bowel sound, duration of hospital stay and cost of hospital stay. Statistical significance was set at a p-value of \<0.05. Version 23 of the Statistical Package for Social Sciences for Windows was used to analyze all data obtained from this study.

02

Conditions studied

  • Ileus Postoperative

Browse trials for

Keywords

  • Gum-chewing
  • Metoclopramide
  • Abdominal
  • Surgery
03

In context

Ileus

167 studies on the registry are indexed under Ileus; 23 are open to participants now.

This study's enrollment of 105 is above the median of 90 across 138 interventional studies indexed under Ileus.

Browse Ileus studies →

Lead sponsor

Ikechukwu Bartholomew Ulasi is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients requiring elective abdominal surgery aged 16-65years

Exclusion criteria

Exclusion Criteria:

  • Abdominal emergency surgeries
  • Structural or functional inability to chew gum
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    Gum-Metoclopramide

    Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and to chew one a stick of sugar free gum (to be chewed over 15minutes) 8 hourly till either first flatus or feces was passed

    Combination Product: Gum and metoclopramide

  • Active comparator
    Gum-only

    Chew one stick of sugar free gum (to be chewed over 15minutes) 8 hourly till either first flatus or feces was passed

    Other: Gum

  • Active comparator
    Metoclopramide-only

    Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively

    Drug: Metoclopramide 10mg

  • Placebo comparator
    Control

    10ml of sterile water intravenously 8hourly for the first 72hours post-operatively

    Other: Control

Interventions

  • Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively

    Also known as: Philometro, Hubei Tianyao

  • Combination productGum and metoclopramide

    Drug page: Metoclopramide

    Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and one stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed

  • OtherGum

    One stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed

  • OtherControl

    10ml of sterile water intravenously 8hourly for the first 72hours post-operatively

06

What researchers measure

Primary outcomes

  1. Duration of post-operative ileus

    Time to either the passage of flatus or feces, assessed every 8hours from post-operative day 1

    Time frame: From 24 hours after surgery up to the time either flatus or feces is passed, for up to 1week after surgery

Secondary outcomes

  1. Duration of hospital stay

    Length of in-hospital care after surgery

    Time frame: First post-operative day up to the day of discharge, for up to 25days after surgery

07

Study locations

1 site
  • University College Hospital
    Ibadan, Oyo +234, Nigeria
08

References and documents

Publications

  • Pedziwiatr M, Kisialeuski M, Wierdak M, Stanek M, Natkaniec M, Matlok M, Major P, Malczak P, Budzynski A. Early implementation of Enhanced Recovery After Surgery (ERAS(R)) protocol - Compliance improves outcomes: A prospective cohort study. Int J Surg. 2015 Sep;21:75-81. doi: 10.1016/j.ijsu.2015.06.087. Epub 2015 Jul 29. PubMed 26231994 ↗
  • COHEN J. The statistical power of abnormal-social psychological research: a review. J Abnorm Soc Psychol. 1962 Sep;65:145-53. doi: 10.1037/h0045186. No abstract available. PubMed 13880271 ↗
  • Delaney C, Kehlet H, Senagore AJ, Bauer AJ, Beart R, Billingham R, et al. Postoperative ileus: profiles, risk factors, and definitions - a framework for optimizing surgical outcomes in patients undergoing major abdominal colorectal surgery. In: Bosker G, editor. Clinical consensus update in general surgery; 2006 May 1; Massachusetts United States. Roswell (GA): Pharmatecture, LLC; 2006. p. 1-26.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Sep 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2022
First posted
Jan 3, 2023
StartActual
Oct 1, 2018
Primary completionActual
Sep 30, 2019
CompletionActual
Sep 30, 2019
Last update
Jan 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05669781
Lead sponsor
Ikechukwu Bartholomew Ulasi
Responsible party
Ikechukwu Bartholomew Ulasi (Principal investigator, University College Hospital, Ibadan) — Sponsor-investigator
First posted
Jan 3, 2023
Start date
Oct 1, 2018
Primary completion
Sep 30, 2019
Completion
Sep 30, 2019
Last update
Jan 3, 2023

Study contacts

Ikechukwu B. Ulasi
principal investigator · University College Hospital, Ibadan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metoclopramide

Start the discussion